William Dougall

William Dougall

UNVERIFIED PROFILE

Are you William Dougall?   Register this Author

Register author
William Dougall

William Dougall

Publications by authors named "William Dougall"

Are you William Dougall?   Register this Author

65Publications

1576Reads

40Profile Views

Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.

Clin Transl Immunology 2019 27;8(10):e01081. Epub 2019 Sep 27.

Immunology in Cancer and Infection Laboratory QIMR Berghofer Medical Research Institute Herston Qld Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cti2.1081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763724PMC
September 2019

Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.

Urol Oncol 2018 11 28;36(11):502.e15-502.e24. Epub 2018 Aug 28.

Department of Urology, University Medicine at the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at the University of California, Los Angeles, CA; Institute of Medical Biochemistry and Molecular Medicine, University Medicine at the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2018.07.013DOI Listing
November 2018

Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.

Nat Rev Clin Oncol 2018 11;15(11):676-693

Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0095-y
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0095-yDOI Listing
November 2018

An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.

Oncoimmunology 2018 5;7(12):e1480301. Epub 2018 Sep 5.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1480301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279336PMC
September 2018

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Oncoimmunology 2018 14;7(6):e1431088. Epub 2018 Feb 14.

Department of Immunology, Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2018.1431088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980384PMC
February 2018

Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method.

Appl Immunohistochem Mol Morphol 2017 May/Jun;25(5):299-307

*Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles ‡Dako, an Agilent technologies company, Carpinteria ∥Department of Comparative Biology and Safety Sciences ¶Formerly Department of Pathology, Amgen Inc., Thousand Oaks, CA †Formerly Department of Pathology §Department of Oncology Research, Amgen Inc., Seattle WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAI.0000000000000503DOI Listing
November 2017

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Clin Cancer Res 2017 Oct 20;23(19):5789-5801. Epub 2017 Jun 20.

Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0606DOI Listing
October 2017

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Breast Cancer Res Treat 2017 Jul 17;164(1):57-67. Epub 2017 Apr 17.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-017-4233-5
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4233-5DOI Listing
July 2017

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

Immunol Rev 2017 03;276(1):112-120

Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/imr.12518DOI Listing
March 2017

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Clin Cancer Res 2016 Nov 12;22(21):5183-5188. Epub 2016 Sep 12.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0933DOI Listing
November 2016

RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

Cancer Res 2016 10 1;76(19):5857-5869. Epub 2016 Aug 1.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2745DOI Listing
October 2016

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Nat Med 2016 08 20;22(8):933-9. Epub 2016 Jun 20.

ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research (WEHI), Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4118DOI Listing
August 2016

Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation.

Stem Cells 2016 Apr 13;34(4):1027-39. Epub 2016 Jan 13.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2271DOI Listing
April 2016

Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.

PLoS One 2015 10;10(6):e0128467. Epub 2015 Jun 10.

Department of Molecular Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128467PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464738PMC
March 2016

RANK and RANK ligand expression in primary human osteosarcoma.

J Bone Oncol 2015 Sep 29;4(3):59-68. Epub 2015 Jul 29.

Therapeutic Innovation Unit, Amgen Inc., Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbo.2015.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986823PMC
September 2015

RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase.

Breast Cancer Res Treat 2014 Aug 10;146(3):515-23. Epub 2014 Jul 10.

Department of Surgery, Northwestern University Feinberg School of Medicine, 303 E. Superior Street Lurie 4-111, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3049-9DOI Listing
August 2014

RANK expression as a prognostic and predictive marker in breast cancer.

Breast Cancer Res Treat 2014 Jun 16;145(2):307-15. Epub 2014 Apr 16.

Institute of Pathology, Campus Mitte, Charité University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-2955-1DOI Listing
June 2014

Targeting RANKL in metastasis.

Bonekey Rep 2014 9;3:519. Epub 2014 Apr 9.

Cancer Epigenetics and Biology Program PEBC, Bellvitge Institute for Biomedical Research, IDIBELL , Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bonekey.2014.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007167PMC
June 2014

RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.

J Thorac Oncol 2014 Mar;9(3):345-54

*Department of Hematology/Oncology Research, Amgen Inc., Seattle, Washington; and †Therapeutic Innovation Unit, Amgen Inc., Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000070DOI Listing
March 2014

RANK expression on breast cancer cells promotes skeletal metastasis.

Clin Exp Metastasis 2014 Feb 24;31(2):233-45. Epub 2013 Nov 24.

Oncology Research, Amgen Washington, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-013-9624-3DOI Listing
February 2014

Progesterone/RANKL is a major regulatory axis in the human breast.

Sci Transl Med 2013 Apr;5(182):182ra55

Swiss Institute for Experimental Cancer Research, National Center of Competence in Research Molecular Oncology, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.3005654DOI Listing
April 2013

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.

Breast Cancer Res Treat 2012 Oct 29;135(3):771-80. Epub 2012 Aug 29.

Department of Oncology Research, Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-012-2222-2DOI Listing
October 2012

Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.

Clin Cancer Res 2012 Jan 26;18(2):326-35. Epub 2011 Oct 26.

Department of Hematology and Oncology Research, Amgen Inc., Seattle, WA 98119, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2507DOI Listing
January 2012

Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Bone 2011 Mar 10;48(3):578-87. Epub 2010 Nov 10.

New England Musculoskeletal Institute, Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT 06030-5456, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2010.11.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039095PMC
March 2011

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Nature 2010 Nov 29;468(7320):103-7. Epub 2010 Sep 29.

Department of Hematology/Oncology Research, Amgen Inc, Seattle, Washington 98119, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature09495DOI Listing
November 2010

Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.

Bone 2009 Jan 26;44(1):160-7. Epub 2008 Sep 26.

Department of Orthopaedic Surgery, The New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, CT 06030-5456, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bone.2008.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657045PMC
January 2009

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.

Mol Cancer Ther 2008 Jul 7;7(7):2160-9. Epub 2008 Jul 7.

Department of Hematology/Oncology Research, Amgen Washington, Seattle, Washington 98119-3105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0046DOI Listing
July 2008

RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

Cancer Treat Rev 2008 Feb 26;34(1):92-101. Epub 2007 Oct 26.

University of Pittsburgh School of Medicine and VA Medical Center, VA Pittsburgh Healthcare System, Research and Development (151-U), Pittsburgh, PA 15240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2007.09.002DOI Listing
February 2008

RANKL inhibition: from mice to men (and women).

Adv Exp Med Biol 2007 ;602:143-50

Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-72009-8_18DOI Listing
December 2007

RANKL signaling in bone physiology and cancer.

Curr Opin Support Palliat Care 2007 Dec;1(4):317-22

Department of Hematology/Oncology Research, Amgen Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=01263393-200712000-000
Publisher Site
http://dx.doi.org/10.1097/SPC.0b013e3282f335beDOI Listing
December 2007

Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.

Mol Cancer Ther 2007 Jun 31;6(6):1701-8. Epub 2007 May 31.

Department of Cellular and Structural Biology MSC 7762, University of Texas Health Science Center at San Antonio, Texas 78229-3900, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482358PMC
June 2007

Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.

Clin Exp Metastasis 2006 16;23(3-4):167-75. Epub 2006 Aug 16.

SkeleTech, Inc., Bothell, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10585-006-9026-xDOI Listing
February 2007

The RANK/RANKL/OPG triad in cancer-induced bone diseases.

Cancer Metastasis Rev 2006 Dec;25(4):541-9

Department of Cancer Biology, Amgen Washington, 1201 Amgen Court West, Seattle, WA 98119, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-006-9021-3DOI Listing
December 2006

Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.

J Bone Miner Res 2006 Oct;21(10):1571-80

Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1359/jbmr.060706DOI Listing
October 2006

[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].

Clin Calcium 2006 Apr;16(4):627- 35

Amgen Inc. Washington, Department of Cancer Biology, Seattle, WA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/CliCa0604627635DOI Listing
April 2006

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.

J Orthop Res 2005 Nov 6;23(6):1475-83. Epub 2005 Jul 6.

Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Center for Health Sciences 76-134, 10833 LeConte Avenue, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.orthres.2005.05.004.1100230634DOI Listing
November 2005

Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.

J Biol Chem 2004 Dec 14;279(52):54841-8. Epub 2004 Oct 14.

Department of Cancer Biology, Amgen Incorporated, Seattle, Washington 98119, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M406392200DOI Listing
December 2004

Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.

Cancer Res 2003 Nov;63(22):7883-90

Department of Pathology, School of Medicine, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0940, USA.

View Article

Download full-text PDF

Source
November 2003

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing.

J Orthop Res 2003 Jul;21(4):676-84

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0736-0266(03)00011-1DOI Listing
July 2003

A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function.

J Biol Chem 2002 Nov 15;277(46):44347-56. Epub 2002 Aug 15.

Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M202009200DOI Listing
November 2002